Cargando…

Atorvastatin Has a Dose‐Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double‐Blind Randomized Controlled Trials

BACKGROUND: Kidney function decreases during the lifetime, and this decline is a powerful predictor of both kidney and cardiovascular outcomes. Statins lower cardiovascular risk, which may relate to beneficial effects on kidney function. We studied whether atorvastatin influences kidney function dec...

Descripción completa

Detalles Bibliográficos
Autores principales: Vogt, Liffert, Bangalore, Sripal, Fayyad, Rana, Melamed, Shari, Hovingh, G. Kees, DeMicco, David A., Waters, David D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512126/
https://www.ncbi.nlm.nih.gov/pubmed/31020900
http://dx.doi.org/10.1161/JAHA.118.010827
_version_ 1783417659479556096
author Vogt, Liffert
Bangalore, Sripal
Fayyad, Rana
Melamed, Shari
Hovingh, G. Kees
DeMicco, David A.
Waters, David D.
author_facet Vogt, Liffert
Bangalore, Sripal
Fayyad, Rana
Melamed, Shari
Hovingh, G. Kees
DeMicco, David A.
Waters, David D.
author_sort Vogt, Liffert
collection PubMed
description BACKGROUND: Kidney function decreases during the lifetime, and this decline is a powerful predictor of both kidney and cardiovascular outcomes. Statins lower cardiovascular risk, which may relate to beneficial effects on kidney function. We studied whether atorvastatin influences kidney function decline and assessed the association between individual kidney function slopes and cardiovascular outcome. METHODS AND RESULTS: Data were collected from 6 large atorvastatin cardiovascular outcome trials conducted in patients not selected for having kidney disease. Slopes of serum creatinine reciprocals representing measures of kidney function change ([mg/dL](−1)/y), were analyzed in 30 621 patients. Based on treatment arms, patients were categorized into 3 groups: placebo (n=10 057), atorvastatin 10 mg daily (n=12 763), and 80 mg daily (n=7801). To assess slopes, mixed‐model analyses were performed for each treatment separately, including time in years and adjustment for study. These slopes displayed linear improvement over time in all 3 groups. Slope estimates for patients randomized to placebo or atorvastatin 10 mg and 80 mg were 0.009 (0.0008), 0.011 (0.0006), and 0.014 (0.0006) (mg/dL)(−1)/y, respectively. A head‐to‐head comparison of atorvastatin 10 and 80 mg based on data from 1 study (TNT [Treating to New Targets]; n=10 001) showed a statistically significant difference in slope between the 2 doses (P=0.0009). From a Cox proportional hazards model using slope as a predictor, a significant (P<0.0001) negative association between kidney function and cardiovascular outcomes was found. CONCLUSIONS: In patients at risk of or with cardiovascular disease, atorvastatin improved kidney function over time in a dose‐dependent manner. In the 3 treatment groups, kidney function improvement was strongly associated with lower cardiovascular risk. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00327418; NCT00147602; NCT00327691.
format Online
Article
Text
id pubmed-6512126
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65121262019-05-20 Atorvastatin Has a Dose‐Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double‐Blind Randomized Controlled Trials Vogt, Liffert Bangalore, Sripal Fayyad, Rana Melamed, Shari Hovingh, G. Kees DeMicco, David A. Waters, David D. J Am Heart Assoc Original Research BACKGROUND: Kidney function decreases during the lifetime, and this decline is a powerful predictor of both kidney and cardiovascular outcomes. Statins lower cardiovascular risk, which may relate to beneficial effects on kidney function. We studied whether atorvastatin influences kidney function decline and assessed the association between individual kidney function slopes and cardiovascular outcome. METHODS AND RESULTS: Data were collected from 6 large atorvastatin cardiovascular outcome trials conducted in patients not selected for having kidney disease. Slopes of serum creatinine reciprocals representing measures of kidney function change ([mg/dL](−1)/y), were analyzed in 30 621 patients. Based on treatment arms, patients were categorized into 3 groups: placebo (n=10 057), atorvastatin 10 mg daily (n=12 763), and 80 mg daily (n=7801). To assess slopes, mixed‐model analyses were performed for each treatment separately, including time in years and adjustment for study. These slopes displayed linear improvement over time in all 3 groups. Slope estimates for patients randomized to placebo or atorvastatin 10 mg and 80 mg were 0.009 (0.0008), 0.011 (0.0006), and 0.014 (0.0006) (mg/dL)(−1)/y, respectively. A head‐to‐head comparison of atorvastatin 10 and 80 mg based on data from 1 study (TNT [Treating to New Targets]; n=10 001) showed a statistically significant difference in slope between the 2 doses (P=0.0009). From a Cox proportional hazards model using slope as a predictor, a significant (P<0.0001) negative association between kidney function and cardiovascular outcomes was found. CONCLUSIONS: In patients at risk of or with cardiovascular disease, atorvastatin improved kidney function over time in a dose‐dependent manner. In the 3 treatment groups, kidney function improvement was strongly associated with lower cardiovascular risk. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00327418; NCT00147602; NCT00327691. John Wiley and Sons Inc. 2019-04-25 /pmc/articles/PMC6512126/ /pubmed/31020900 http://dx.doi.org/10.1161/JAHA.118.010827 Text en © 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Vogt, Liffert
Bangalore, Sripal
Fayyad, Rana
Melamed, Shari
Hovingh, G. Kees
DeMicco, David A.
Waters, David D.
Atorvastatin Has a Dose‐Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double‐Blind Randomized Controlled Trials
title Atorvastatin Has a Dose‐Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double‐Blind Randomized Controlled Trials
title_full Atorvastatin Has a Dose‐Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double‐Blind Randomized Controlled Trials
title_fullStr Atorvastatin Has a Dose‐Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double‐Blind Randomized Controlled Trials
title_full_unstemmed Atorvastatin Has a Dose‐Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double‐Blind Randomized Controlled Trials
title_short Atorvastatin Has a Dose‐Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double‐Blind Randomized Controlled Trials
title_sort atorvastatin has a dose‐dependent beneficial effect on kidney function and associated cardiovascular outcomes: post hoc analysis of 6 double‐blind randomized controlled trials
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512126/
https://www.ncbi.nlm.nih.gov/pubmed/31020900
http://dx.doi.org/10.1161/JAHA.118.010827
work_keys_str_mv AT vogtliffert atorvastatinhasadosedependentbeneficialeffectonkidneyfunctionandassociatedcardiovascularoutcomesposthocanalysisof6doubleblindrandomizedcontrolledtrials
AT bangaloresripal atorvastatinhasadosedependentbeneficialeffectonkidneyfunctionandassociatedcardiovascularoutcomesposthocanalysisof6doubleblindrandomizedcontrolledtrials
AT fayyadrana atorvastatinhasadosedependentbeneficialeffectonkidneyfunctionandassociatedcardiovascularoutcomesposthocanalysisof6doubleblindrandomizedcontrolledtrials
AT melamedshari atorvastatinhasadosedependentbeneficialeffectonkidneyfunctionandassociatedcardiovascularoutcomesposthocanalysisof6doubleblindrandomizedcontrolledtrials
AT hovinghgkees atorvastatinhasadosedependentbeneficialeffectonkidneyfunctionandassociatedcardiovascularoutcomesposthocanalysisof6doubleblindrandomizedcontrolledtrials
AT demiccodavida atorvastatinhasadosedependentbeneficialeffectonkidneyfunctionandassociatedcardiovascularoutcomesposthocanalysisof6doubleblindrandomizedcontrolledtrials
AT watersdavidd atorvastatinhasadosedependentbeneficialeffectonkidneyfunctionandassociatedcardiovascularoutcomesposthocanalysisof6doubleblindrandomizedcontrolledtrials